Literature DB >> 2821883

Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies.

C W Stratton1, C Liu, H B Ratner, L S Weeks.   

Abstract

This study used kill-kinetic methods to provide data on the bactericidal activity of subinhibitory (1/2 X MIC), inhibitory (1 x MIC), and suprainhibitory (4X, 6X, and 8X MIC) concentrations of deptomycin (LY146032) against strains of enterococci compared with those of ciprofloxacin, vancomycin, and ampicillin. Deptomycin was the most active agent tested, as determined by broth microdilution methods, with all strains being inhibited at concentrations less than or equal to 2 micrograms/ml. The kill-kinetic demonstrated that deptomycin had greater activity at all concentrations tested than the other cell wall-active agents; regrowth was seen, however, at lower concentrations. At higher concentrations (6X and 8X MIC), all agents tested demonstrated the same or less bactericidal activity than at 4X MIC, presumably due to the Eagle effect. Nevertheless, these results suggest that further evaluation of deptomycin as a therapeutic agent for serious enterococcal infections is warranted.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821883      PMCID: PMC174863          DOI: 10.1128/AAC.31.7.1014

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  In vitro activity of LY146032 against staphylococci, streptococci, and enterococci.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

2.  Enterococcal endocarditis. An analysis of 38 patients observed at the New York Hospital-Cornell Medical Center.

Authors:  G L Mandell; D Kaye; M E Levison; E W Hook
Journal:  Arch Intern Med       Date:  1970-02

3.  Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall.

Authors:  D J Krogstad; A R Pargwette
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

4.  Optimal therapy for enterococcal endocarditis.

Authors:  J Herzstein; J L Ryan; R J Mangi; T P Greco; V T Andriole
Journal:  Am J Med       Date:  1984-02       Impact factor: 4.965

5.  Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis.

Authors:  B E Murray; B Mederski-Samaroj
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

Review 6.  Combination antibiotic therapy of bacterial endocarditis.

Authors:  M A Sande; W M Scheld
Journal:  Ann Intern Med       Date:  1980-03       Impact factor: 25.391

7.  Enterococcal endocarditis.

Authors:  C J Wilkowske
Journal:  Mayo Clin Proc       Date:  1982-02       Impact factor: 7.616

8.  Antibiotic-induced lysis of enterococci.

Authors:  G A Storch; D J Krogstad
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

Review 9.  Antibiotic treatment of infective endocarditis.

Authors:  W R Wilson; J E Geraci
Journal:  Annu Rev Med       Date:  1983       Impact factor: 13.739

10.  High-level resistance to gentamicin in clinical isolates of enterococci.

Authors:  B D Mederski-Samoraj; B E Murray
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

View more
  21 in total

1.  Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model.

Authors:  K Vance-Bryan; T A Larson; J C Rotschafer; J P Toscano
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

2.  Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Authors:  Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 3.  Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s.

Authors:  R C George; A H Uttley
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

4.  Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.

Authors:  P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

5.  In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.

Authors:  D F Sahm; J Kissinger; M S Gilmore; P R Murray; R Mulder; J Solliday; B Clarke
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium.

Authors:  N Mobarakai; J M Quale; D Landman
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 8.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

9.  In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.

Authors:  K C Lamp; M J Rybak; E M Bailey; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

10.  Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.

Authors:  H Hanberger; L E Nilsson; R Maller; B Isaksson
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.